Stem Like Cells and Androgen Deprivation in Prostate Cancer by Yao Tang et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Stem Like Cells and Androgen  
Deprivation in Prostate Cancer 
Yao Tang, Mohammad A. Khan, Bin Zhang and Arif Hussain 
University of Maryland School of Medicine and Baltimore VA Medical Center 
USA 
1. Introduction 
Cancer stem cells (CSC) have been hypothesized to contribute to tumor initiation and 
recurrence, but the very existence of CSC is currently under debate. Increased expression of 
stem cell markers in cancer tissues after various treatments has been observed in both 
experimental animal models and patients for a number of cancer types. Cancer cells that 
express stem cell markers are generally called stem-like cells (SLC) since the exact origin of 
these cells is often not clear. 
Using human LNCaP prostate cancer cell-based mouse xenografts as well as a transgenic 
model of prostate cancer (TRAMP), we studied the possible origin of SLC and their potential 
role in cancer recurrence after androgen deprivation therapy (ADT). We found that the 
proportion of SLC within a tumor can change over time, particularly after anti-cancer 
therapy (Tang et al., 2010). A significant increase in the SLC population occurred in tumors 
soon after ADT (surgical castration), but then returned to basal levels when the tumors 
resumed growth after the initial response to ADT. Several stem cell markers were found to 
be elevated during this period. This phenomenon was observed in both LNCaP xenografts 
and in TRAMP mice. These observations suggest that ADT may induce a ‘stemness’ stage in 
tumors which, although transient, could allow tumor cells to adapt to the anti-tumor effects 
of ADT and enhance their survival. A similar phenomenon was observed in LNCaP 
xenografts after docetaxel treatment. We believe stemness may have a biological function in 
self protection; it may be one pathway by which tumor cells can survive and recur after anti-
cancer treatment.  
2. Cancer stem cell or cancer cell stemness 
The concept of cancer stem cells (CSC) is built upon the hypothesis that tumor tissues 
harbor a very small population of cells that is responsible for tumor initiation and 
recurrence due to its capacity for self-renewal and multilineage differentiation, as well as 
relative drug resistance. However, the frequency of CSC can be highly variable among 
different tumor types, and even among tumors of the same type (Visvader & Lindeman, 
2008). For instance, in clinical samples, the CSC population in melanomas (ABCB5+) ranges 
between 1.6 - 20% (Schatton et al., 2008), and in colorectal carcinomas (CD133+) between 1.8 
- 24.5% (O'Brien et al., 2007). The factors governing the different frequencies of CSC within 
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tumors are not clearly delineated, although communication with surrounding cells and 
stroma, alterations in pH, chemokines/cytokines in the microenvironment, locoregional 
angiogenesis, and host response to local tissue damage could all potentially affect the CSC 
population to varying degrees.  
A number of cell surface markers have been used to identify CSC in human cell cultures 
and in vivo experiments, including CD44, CD133, and c-Kit, among others. The relevance 
of some of the common stem cell markers such as CD44 with respect to stem-cell like 
properties and growth characteristics, however, is not altogether clear, particularly in 
established long term cell culture lines. For instance, in human prostate cancer cell lines, 
CD44 has been used to identify CSC; isolated CD44+ cells from prostate cancer cell lines 
and xenograft tumors show stem-like functions in terms of self-renewal, clonogenicity, 
tumorigenicity, as well as tumor metastasis (Patrawala et al., 2006; H. Li et al., 2008). 
However, significant differences in CD44 expression can exist between various prostate 
cancer cell lines in culture. For instance, by flowcytometry, CD44+ cells can represent 80-
90% of the population in PC3 and DU145 cell lines (Patrawala et al., 2006; H. Li et al., 
2008), but in LNCaP they are undetectable. The side population (SP) assay, which is based 
on exclusion of vital dyes, has also been used to identify a small subpopulation of cells 
enriched in self-renewal function particularly that derived from the bone marrow 
(Goodell et al., 1996). No difference in SP fractions is observed among PC3, DU145 and 
LNCaP cell lines, and their relevance to the overall biology of these cancer cells is not 
clear.  
A recent comprehensive analysis of stem cell makers in the NCI60 Tumor Cell Line Panel 
demonstrates the presence of these various markers, but they are expressed in rather 
complex combinatorial patterns in cancer cell lines of different lineages (Stuelten et al., 
2010). This and other studies suggest that established immortal cancer cell lines harbor SLC 
subpopulations, but also underscore the complexity of stem cell biology. Although 
mounting evidence supports the existence of CSC in various types of tumors (Baker, 2008; 
Dalerba et al., 2007; Lobo et al., 2007; C. Tang et al., 2007; Huntly & Gilliland, 2005), how 
cells with stem cell like-properties affect the growth characteristics and/or metastatic 
potential of tumors still remains an open question (Dalerba et al., 2007; Fabian et al., 2009; 
Jordan, 2009; Marotta & Polyak 2009; Clevers, 2011).  
Another term, stemness, is frequently used in stem cell studies, but its exact definition has 
not been universally accepted (Leychkis et al., 2009; Hoffmann & Tsonis, 2011). Epithelial-
mesenchymal and mesenchymal-epithelial transition states are also relevant not only to 
embryogenesis but to tumorigenesis; how these may relate to stemness is an area of active 
investigation ((Yang & Weinberg, 2008). In general, stemness represents a state in which cells 
are characterized by self-renewal and plasticity. In cancer tissue, the stemness state may be a 
transiently acquired property by a subpopulation of tumor cells that likely also involves 
input from surrounding cells. Biological or pharmacological stress, or changes in the tumor 
microenvironment, could serve as potential triggers for inducing this state, which may then 
allow for adaptation, survival and eventual disease progression.  
3. Anti-tumor therapy and stem like cells in prostate cancer 
Over the last several years we have utilized an LNCaP-based xenograft model and a 
genetically engineered transgenic mouse model, TRAMP, to study the effects of androgen 
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deprivation and chemotherapy on prostate cancer (Y. Tang et al., 2006, 2008, 2009, 2010). 
Tumor tissues were collected at different time points before and after various treatments, 
and the expression patterns of several stem cell markers were evaluated in an effort to better 
understand treatment response and potential mechanisms of tumor recurrence. 
3.1 LNCaP xenograft based studies 
LNCaP is a hormone-sensitive human prostate cancer cell line. Withdrawal of androgens in 
vitro interrupts its growth and induces apoptosis. In vivo, LNCaP tumors in male SCID 
mice cease growth for up to 2-3 weeks after surgical castration (bilateral orchiectomy), 
which is invariably followed by accelerated tumor growth (Figure 1A). 
Immunohistochemical (IHC) analysis of proliferation-related (Ki67) and angiogenesis-
related (CD105) markers in castrated and non-castrated mice is shown in Figures 1B and 
1C. It is apparent that a significant decrease in overall proliferation occurs only in the 
castrated mice between one and two weeks after castration, followed then by recovery of 
proliferative potential. This recovery of cell proliferation appears to parallel increased 
angiogenesis, which is observed at the IHC level between two and three weeks post 
castration. In non-castrated mice, on the other hand, tumors continue to grow unabated 
over time, with no observable changes in cell proliferation or overall angiogenesis noted 
over this period of continued growth (Figures 1A-C). 
To determine whether SLC play any role in the above model, we also studied several stem 
cell markers. Recent studies suggest that SLC are a heterogeneous population with diverse 
biological properties, and that multiple subpopulations with stem cell-like characteristics 
can coexist in the same tumor (Hermann et al., 2007; Ma et al., 2008; Hope et al., 2004). Since 
there is no single specific ‘standard’ marker for identifying cancer stem cells, we selected 
several antigens that have been implicated in one way or the other in stem cell biology; 
specifically, CD44, CD133, and c-Kit (CD117) for IHC studies, and human ALDH (aldehyde 
dehydrogenase), Shh (sonic hedgehog), p63, BCRP (breast cancer resistant protein), Notch1 
and bcl-2 for western blot analyses. Tumor samples were collected at days 5, 10, 15, 20, 25, 
and 30 post castration, and tumors from non-castrated mice collected at similar time points 
served as controls. 
By IHC, expressions of c-Kit (Figure 1D) and CD44 (Figure 1E), but not CD133, were 
significantly increased in LNCaP xenograft tumors at the day 15 time point after castration 
but not at other time points in either castrated or control mice. Representative images of c-
Kit and CD44 at day-15 (Cas-15) and day 30 (Cas-30) are shown in Figure 1E. Interestingly, 
we noted that the distribution of CD44+ and c-Kit+ cells in tumor tissues was different. 
Most of the CD44+ cells were found in the periphery of tumor islands, whereas c-Kit+ cells 
were present within the tumor mass (Figure 1E). This suggests that these two proteins can 
be expressed in different cells within the LNCaP tumors, and may potentially signify the 
presence of different subtypes of SLC in these tumors. In untreated control mice, on the 
other hand, SLC markers do not change significantly over time despite continued tumor 
growth, as shown in Figure 1D. 
Data for several proteins evaluated by western blots are summarized in Table 1. It is 
apparent from these initial studies that there is a trend for Shh, Notch, ALDH, BCRP and 
p63 to be over expressed at least 2-fold at day 15 compared to the other time points post 
castration in most or all the tumor samples tested, while Bcl2 is over expressed in 2 of the 4 
tumors evaluated at this time point.  
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A. Relative tumor volumes at different time points. Male SCID mice (6-8 wks of age), were inoculated sq with 5 x 
106 LNCaP cells per flank. The tumor volumes are shown as the average tumor volume at each time point (5-10 
mice) divided by the average tumor volume at day 0. B-D. Protein expression patterns are summarized as 
histographs based on IHC data. Cryosections or FFPE (formalin-fixed paraffin-embedded) tissue sections of 
tumors from each time point (n=4-5) were analyzed for the expression of Ki67 (B), CD105 (C), and c-Kit (D). 
Five to ten images per section were taken randomly and digitized using the autoscan function of MCID 7.0 
software which was set with respect to grain counts (CD105, Ki67) or positively staining cells (c-Kit). Data were 
analyzed using SigmaPlot. E. Representative images demonstrating expressions of CD44 and c-Kit in tumors at 
days 15 (Cas-15) and 30 (Cas-30) post castration. (Amplification: 200x). 
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We also carried out pilot studies with docetaxel chemotherapy in the LNCaP xenografts 
(Figure 2). Specifically, LNCaP-bearing SCID mice were treated with docetaxel when 
tumour volumes reached approximately 300 cc (docetaxel was given IP at 8 mg/kg every 3 
to 4 days X 4 doses over a two week period). Tumors were harvested from the mice at  
 
 
A. Tumor volumes at different time points. Arrows indicate start and end of docetaxel treatments. B. 
Representative western blot. Expressions of ALDH and Shh at different time points from start of treatment were 
determined in tumor samples (n=5 per time point). C. IHC. c-Kit expression in various tumor tissues. The 
selected images are representative of 3-5 tumors per time point. Five to 10 images per slide were taken and 
digitized using MCID 7.0 software. Data were analyzed with SigmaPlot and plotted using Microsoft Excel. 
Fig. 2. Evaluation of LNCaP tumors in docetaxel-treated mice.  
 
 
Equal amounts of protein from 3-5 tumors at each time point were analyzed with western blots. After 
normalization to actin, at least double the mean of the band intensities with respect to the non-castrated control 
samples in each reaction was considered to be overexpressed. ND: not done. 
Table 1. The expression of stem cell markers in LNCaP xenografts post castration.  
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different time points post docetaxel treatment as shown in Figure 2A, and evaluated for 
ALDH and Shh expression by western blots and for c-Kit expression by IHC (Figures 2B and 
2C). Although our analysis is limited, interestingly, as is the case with castrated mice, 
increased levels of ALDH, Shh and c-Kit were observed in the docetaxel treated mice at 
points of maximal anti-tumor response (Figures 2A-C). These initial studies suggest that 
docetaxel treatment can also induce enhanced expression of some of the proteins associated 
with SLC, although the kinetics of this response are somewhat different than observed in 
tumors from castrated mice. Thus, there is a trend towards enhanced expression of SLC-
related proteins in both castrated mice and docetaxel treated mice at points of maximal anti-
tumor response (i.e. when tumors are at their smallest sizes).  
3.2 TRAMP based studies 
A similar phenomena of enhanced SLC expression post castration was also observed in the 
TRAMP model in which probasin promoter-driven T antigen expression in mouse prostatic 
epithelia induces prostate cancers in male mice as they mature sexually (by 8 to 12 weeks of 




A. Effects of castration on genitourinary (GU) organs. Based on G/B ratios (GU organs versus mouse body 
weight), TRAMP mice were divided into two groups after castration – those with G/B ratios ≤ 3.0 (Cas-S) and 
others with G/B ratios > 20 (Cas-L). B. IHC. Expressions of CD133 and Sca-1 in TRAMP mouse prostates. These 
proteins are highly expressed in Cas-S tumors around 5 (Cas-S 5wk; n=3) and 10 wks (Cas-S 10wk; n=3) post 
castration, but not in Cas-L tumors (n=3). Prostate tumors from non-castrated mice (intact; n=3) and normal 
prostate tissues from wild-type siblings (n=3) served as controls.  
Fig. 3. Evaluation of tumors in TRAMP mice.  
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We previously reported that castration of these mice at 12 weeks of age resulted in two 
different outcomes with respect to anti-tumor response (Y. Tang et al., 2008). In one group of 
mice, significant locoregional disease progression occurred subsequent to the castration 
without any evidence of tumor shrinkage such that the mice ended up with large prostatic 
tumors (designated Castration-Large or Cas-L); in these mice, the average genitourinary 
(GU) organ weight (which included prostate gland and seminal vesicles) to total body 
weight (G/B) ratios were 25.43 ± 5.25 (Figure 3A) (Y. Tang et al., 2008). Other mice 
(designated Castration-Small or Cas-S) had a positive response to castration in that 
prominent shrinkage of the prostate gland and other GU organs occurred so that the 
average G/B ratios were around 1.41 ± 1.31 (Figure 3A); despite a positive response to 
castration the prostate glands still harbored cancer cells. Analysis of two SLC markers, Sca1 
(which is mouse-specific) and CD133, in mice responding positively to castration (i.e. small 
G/B ratios) revealed significant increase of both markers at weeks 5 (Cas-S 5wk) and 10 
(Cas-S 10wk) (Figure 3B). By contrast, in Cas-L tumors and in tumors from non-castrated 
mice, Sca1 and CD133 levels remained low (Figure 3B).  
4. Discussion 
The above studies indicate that enhanced expression of SLC-related proteins can occur in 
prostate tumors in response to anti-proliferative/cytotoxic treatments such as androgen 
deprivation or chemotherapy. Further, this SLC response appears to be transient in nature in 
that it is generally limited to the time period of maximal anti-tumor response to treatment.  
The increased expression of these SLC-related proteins observed in our tumor samples could 
be due to more proteins being expressed per cell but within a limited number of the cells, or 
alternatively more cells that express these proteins (but not necessarily at significantly higher 
levels than baseline) may be recruited, or it could be a combination of these two processes. 
Regardless of the specifics of the underlying processes associated with each individual protein 
in terms of patterns and mechanisms of expression, our results indicate that the overall 
expressions of several SLC markers in tumors change as a function of time post treatment. 
These transient elevations of a relatively broad range of stem cell markers indicate a complex 
tissue response in which not only tumor cells but other surrounding cells could be involved. 
We hypothesize that this transient period represents a stemness stage during which cancer 
cells and surrounding cells can adapt to a changed microenvironment. 
Elevations of stem cell related proteins have also been observed by others. For instance, 
CD44 over expression in breast cancer patients after chemotherapy (X. Li et al., 2008), CD133 
over expression in human glioblastoma after radiation (Bao et al., 2006), and ALDH1 over 
expression and increased enzyme activity in human colorectal xenograft tumors after 
chemotherapy (Dylla et al., 2008) have been reported. Other forms of stress such as hypoxia 
and products of metabolism, including lactate and ketones, have also recently been shown 
to induce stemness in tumor tissues (Kim et al., 2009; Martinez-Outschoorn et al., 2011). 
Thus, emerging data suggest a correlation between SLC and anti-cancer therapy or other 
forms of cellular stress, although the exact role of the SLC population in tumor recurrence 
remains unclear.  
Xin et al have shown that prostate glands in C57BL6 wild type mice undergoing castration 
are enriched in Sca1+ cells, and which are found primarily in the relatively treatment-
resistant G0 phase of the cell cycle (Xin et al., 2005). These cells are capable of regenerating 
tubular structures containing basal cells and luminal cells in a dissociated prostate 
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regeneration system, demonstrating their plasticity and role in prostate regeneration. 
Moreover, enriched SLC populations have been reported in several tumor-free tissues 
following local damage (Beltrami et al., 2003; Amcheslavsky et al., 2009). Thus, stemness may 
represent a protective response by tissue cells, including cancerous cells, to damage or 
environmental change. This stemness state may in turn allow cells to survive, adapt and grow.  
Stemness is not an unusual characteristic; many cells possess this ability. As indicated by 
Zipori et al, all cells possess the molecular machinery that enables them to return to a 
relatively undifferentiated stem cell-like state when appropriately challenged (Zipori, 2009). 
Several recent studies have also documented de-differentiation in mature cells (Brawley & 
Matunis, 2004; Monje et al., 2010; Red-Horse et al., 2010; Shoshani & Zipori, 2011) During 
tumor recurrence/progression, the de-differentiated SLC can re-differentiate back into the 
original tumor, or under other conditions, they could trans-differentiate to a different 
phenotype. Our TRAMP mice castrated at 12 weeks of age all eventually developed prostate 
cancer, including distant metastasis in over 70% of the animals (Y. Tang et al., 2008, 2009). In 
several of these mice, neuroendocrine carcinoma (NEC) partially or completely replaced the 
original adenocarcinomas in the prostate gland and/or distant metastatic sites (Y. Tang et 
al., 2009); this was rarely observed in the non-castrated mice. Thus, in TRAMP mice 
regrowth after castration can lead to ‘differentiation’ along the same original 
adenocarcinoma pathway or trans-differentiation along the NEC pathway. 
A recent study showed that certain differentiated cells in breast tissue spontaneously converted 
to a stem cell-like state (Chaffer et al., 2011). This challenges the scientific dogma that 
differentiation is a one way path, i.e. once cells specialize they cannot return to a SLC state on 
their own. Thus, a considerable degree of plasticity exists among cells in their ability to 
reprogram themselves to a more permissive state not only when appropriately challenged, but 
under certain conditions this seems to occur spontaneously. The state of ‘stemness’ that occurs 
in response to androgen deprivation in our xenograft and transgenic prostate cancer models 
appears to be transient. Interestingly, recent work has shown that cancer cells in culture 
exposed to various drugs can undergo histone deacetylation mediated chromatin changes that 
result in transient reversible drug tolerant states (Sharma et al., 2010). 
5. Conclusion 
The transient nature of various adaptive responses noted above suggests that to maximize 
anti-cancer treatments, not only more effective agents need to be developed, but also the 
relative timing of these treatments with respect to the transient cellular states need to be 
taken into account. Thus, given that various adaptive cellular processes are dynamic, real 
time detection and targeting of cancer cells undergoing de-differentiation may improve the 
efficacy of anti-cancer therapies.  
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